Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company based in Sarasota, Florida, dedicated to the discovery and development of a novel class of anti-infective agents. The company's proprietary technology platform, known as Bisphosphocins™, consists of synthetic, small-molecule compounds designed to address the growing global threat of multi-drug resistant (MDR) bacterial, viral, and fungal infections. Unlike traditional antibiotics that often target specific metabolic pathways, Bisphosphocins utilize a unique mechanism of action that rapidly disrupts the bacterial cell membrane. This physical mode of action makes it significantly more difficult for pathogens to develop resistance, offering a potential breakthrough for patients who have exhausted conventional treatment options. The company's lead product candidate, Nu-3, is being developed as a topical and systemic antimicrobial. It has been studied for the treatment of infected diabetic foot ulcers and other chronic wounds where biofilm and resistant bacteria are prevalent. Beyond wound care, Lakewood-Amedex is exploring the application of its platform for respiratory tract infections and other systemic indications. The company aims to leverage its intellectual property and clinical data to form strategic partnerships and advance its pipeline through the regulatory approval process to meet the urgent need for effective new anti-infectives.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!